Management Presentation: Biosimilar Pipeline and Margin Improvement Strategy
Attractive market fundamentals | Leadership and scale | Multiple growth drivers | Margin improvement | Attractive financial outlook | Compelling sustainability story
Attractive and growing market with
increasing share in Biosimilars
Off-patent market1
Gross sales, in USD bn
208
23
185
2022
Generics
Biosimilars
Key drivers
420
CAGR
'22-'31
Supportive demographic trends
+8%
122
+20%
Challenged healthcare systems
Growing value of loss
of exclusivity
298
+5%
2031
1. Based on Company analysis using IQVIA Analytics Link MAT12-2022 data in LCUSD at gross price, excludes certain sizeable markets with no or limited
Sandoz operations; 2022-2031 CAGR for Biocomparable, Early Entry Generics and Generics as defined by IQVIA and includes all ATC and NFC forms
10
Management Presentation
Shifting share towards Biosimilars
Increasing market adoption of
Generics and Biosimilars
SANDOZView entire presentation